Stock comparison
Haleon
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HLN
Haleon
Market cap
$41.25B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HLN | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 54D | 75B | IDXX |
| Benjamin Graham | 55C | 80A | IDXX |
| Philip Fisher | 49D | 75B | IDXX |
| Peter Lynch | 54C | 71B | IDXX |
| Joel Greenblatt | 49D | 83C | IDXX |
| Charlie Munger | 47D | 87A | IDXX |
| Terry Smith | 43D | 84A | IDXX |
Side-by-side metrics
| Metric | HLN | IDXX |
|---|---|---|
| Market cap | $41.25B | $44.12B |
| P/E (TTM) | 28.8x | 39.0x |
| EV/EBIT | 35.6x | 31.6x |
| ROIC (TTM) | 4.13% | 40.66% |
| Gross margin | 61.45% | 62.05% |
| Net margin | 12.59% | 24.63% |
| Revenue CAGR 5y | 3.11% | 7.56% |
| EPS CAGR 5y | 4.66% | 10.79% |
| Debt / Equity | 0.5x | 0.7x |
| Dividend yield | 2.15% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HLN leads on
- Dividend yield2.15%vs 0.0%+100%
- P/E (TTM)28.8xvs 39.0x+26%
- Debt / Equity0.5xvs 0.7x+25%
IDXX leads on
- ROIC (TTM)40.66%vs 4.13%+90%
- Revenue CAGR 5y7.56%vs 3.11%+59%
- EPS CAGR 5y10.79%vs 4.66%+57%
- Net margin24.63%vs 12.59%+49%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.